Diaceutics (LON:DXRX) receives buy rating from Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on the stock Diaceuticals (LON:DXRX – Free Report) in a research report released on Tuesday morning, MarketBeat Ratings reports. Canaccord Genuity Group currently has a GBX 160 ($2.08) price objective on the stock.

Diaceutics stock performance

DXRX opened at GBX 128 ($1.66) on Tuesday. The company has a quick ratio of 9.92, a current ratio of 6.40, and a debt-to-equity ratio of 2.95. The company has a market cap of £108.11 million, a price-to-earnings ratio of -6,400.00 and a beta of 0.57. Diaceutics has a 52 week low of GBX 82 ($1.07) and a 52 week high of GBX 136 ($1.77). The company’s fifty day simple moving average is GBX 126.81, and its two hundred day simple moving average is GBX 113.49.

Diaceutics Company Profile

(Get a free report)

Diaceutics PLC, a diagnostics commercialization company, provides data, data analysis and implementation services to pharmaceutical companies worldwide. It operates the DXRX platform, which provides DXRX data solutions, including access to various diagnostic test data pipelines from a network of laboratories that provide DXRX signal, laboratory mapping, test dashboard and physician mapping services; DXRX Marketplace Solutions, which enables a marketplace where labs, pharmaceuticals, and diagnostic companies come to find partners for precision medicine diagnostic collaborations.

Further reading

Get news and reviews for Diaceutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Diaceutics and related companies with MarketBeat.com’s FREE daily email newsletter.